LivaNova PLC (NASDAQ:LIVN) Signals Consolidation With Potential To Re-accelerate

Momentum shows a short pause while fundamentals present mixed efficiency and improving cash coverage; near-term price action likely consolidates before any meaningful directional move.

Recent News

On February 25, 2026 the company issued a corporate release referenced broadly across outlets that included non-operational updates and executive-level changes. A Form 4 filing on December 17, 2025 recorded an insider purchase by a company vice president. The company published a UK tax strategy document dated January 1, 2026.

Technical Analysis

Directional indicators show a developing trend strength: ADX at 24.41 indicates an emerging trend rather than a dominant one; DI- at 29.13 increasing and DI+ at 15.06 decreasing together signal directional pressure to the downside, which supports a near-term bearish tilt against valuation support levels.

MACD sits negative at -0.11 and trends lower while the signal line stands at 0.74; the negative, declining MACD below its signal line signals bearish momentum and reduces the probability of an immediate upward impulse linked to valuation re-rating.

MRO reads 17.37 and is decreasing; because MRO remains positive, price sits above the model target and thus carries a higher likelihood of downward mean-reversion toward valuation-aligned levels.

RSI at 52.63 and decreasing indicates momentum loss from neutral territory rather than overbought conditions, implying consolidation around current prices rather than a rapid breakout.

Price relationships show the stock trading at $61.93, below the 20-day average of $67.29 and the 12-day EMA of $65.63 (both decreasing), while remaining above the 200-day average of $55.25. This configuration favors a consolidation band bounded by short-term moving averages with longer-term support still intact, consistent with WMDST’s valuation context.

Bollinger bands place the 1x lower band at $63.77 and the 1x upper at $70.81; the close sits just inside the lower half of the band structure, reinforcing the consolidation-with-downside-bias narrative while volatility measures (42-day 2%) remain modest.

 


Fundamental Analysis

Revenue totaled $360,921,000 for the period under review. YoY revenue growth signals remain mixed in the provided metrics; reported revenue growth reads as effectively flat on the core metric. Gross margin holds at 66.434%, supporting operating leverage despite top-line variability.

Operating income reached $42,578,000 with an operating margin of 11.80%, while EBIT equals $38,491,000 producing an EBIT margin of 10.67%. QoQ the EBIT margin contracted roughly -14.8% and YoY contracted approximately -52.5%, showing near-term margin compression versus the trailing period. Compared with the industry peer mean EBIT margin of 20.867% and industry peer median of 20.883%, the company’s EBIT margin sits below the industry peer mean and median.

EPS for the latest report registered $0.86 versus an estimate of $0.81, an EPS upside of $0.05 or a 6.17% surprise, the positive beat reflected in the reported net income of $30,906,000. Free cash flow reached $50,164,000, producing a free cash flow yield of 1.45%, which sits above the industry peer mean free cash flow yield of 0.909% (industry peer mean expressed as 0.91%).

Balance-sheet metrics show $635,552,000 in cash and cash equivalents and a cash ratio of 0.79, supporting liquidity while total debt equals $433,772,000. Debt-to-EBITDA registers about 8.15x, indicating elevated leverage relative to operating cash flow coverage and implying limited cushion against sustained operating weakness. Return on equity reads roughly 2.58% and return on assets about 1.20%, levels that signal modest capital efficiency versus longer-term targets.

Valuation multiples show a trailing P/E around 73.5 and a forward P/E near 51.0; price-to-book sits at 2.88 versus an industry peer mean price-to-book of 5.98, placing book multiple below the industry peer mean. Enterprise multiple measures (enterprise multiple ≈ 61.12) reflect a premium on enterprise value relative to current operating earnings. The current valuation as determined by WMDST: under-valued.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-02-25
NEXT REPORT DATE: 2026-05-27
CASH FLOW  Begin Period Cash Flow 646.1 M
 Operating Cash Flow 82.4 M
 Capital Expenditures -32.23 M
 Change In Working Capital 19.1 M
 Dividends Paid
 Cash Flow Delta -10.53 M
 End Period Cash Flow 635.6 M
 
INCOME STATEMENT REVENUE
 Total Revenue 360.9 M
 Forward Revenue 182.5 M
COSTS
 Cost Of Revenue 121.1 M
 Depreciation 10.2 M
 Depreciation and Amortization 14.7 M
 Research and Development 52.1 M
 Total Operating Expenses 318.3 M
PROFITABILITY
 Gross Profit 239.8 M
 EBITDA 53.2 M
 EBIT 38.5 M
 Operating Income 42.6 M
 Interest Income 4.5 M
 Interest Expense 10.9 M
 Net Interest Income -6.40 M
 Income Before Tax 27.6 M
 Tax Provision -3.28 M
 Tax Rate 21.0 %
 Net Income 30.9 M
 Net Income From Continuing Operations 30.9 M
EARNINGS
 EPS Estimate 0.81
 EPS Actual 0.86
 EPS Difference 0.05
 EPS Surprise 6.173 %
 Forward EPS 1.14
 
BALANCE SHEET ASSETS
 Total Assets 2.6 B
 Intangible Assets 1.0 B
 Net Tangible Assets 177.2 M
 Total Current Assets 1.1 B
 Cash and Short-Term Investments 635.6 M
 Cash 635.6 M
 Net Receivables 216.0 M
 Inventory 164.7 M
 Long-Term Investments 15.7 M
LIABILITIES
 Accounts Payable 97.2 M
 Short-Term Debt 31.5 M
 Total Current Liabilities 808.1 M
 Net Debt
 Total Debt 433.8 M
 Total Liabilities 1.4 B
EQUITY
 Total Equity 1.2 B
 Retained Earnings -1.15 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 21.96
 Shares Outstanding 54.649 M
 Revenue Per-Share 6.60
VALUATION
 Market Capitalization 3.5 B
 Enterprise Value 3.3 B
 Enterprise Multiple 61.124
Enterprise Multiple QoQ 35.625 %
Enterprise Multiple YoY 131.934 %
Enterprise Multiple IPRWA high: 158.913
median: 85.622
mean: 83.436
LIVN: 61.124
low: -144.328
 EV/R 9.009
CAPITAL STRUCTURE
 Asset To Equity 2.172
 Asset To Liability 1.853
 Debt To Capital 0.266
 Debt To Assets 0.166
Debt To Assets QoQ -12.505 %
Debt To Assets YoY -38.356 %
Debt To Assets IPRWA high: 0.717
mean: 0.28
median: 0.262
LIVN: 0.166
low: 0.009
 Debt To Equity 0.361
Debt To Equity QoQ -14.023 %
Debt To Equity YoY -29.482 %
Debt To Equity IPRWA high: 2.909
mean: 0.537
median: 0.472
LIVN: 0.361
low: 0.01
PRICE-BASED VALUATION
 Price To Book (P/B) 2.878
Price To Book QoQ 16.318 %
Price To Book YoY 42.599 %
Price To Book IPRWA high: 10.911
mean: 5.981
median: 5.854
LIVN: 2.878
low: 0.42
 Price To Earnings (P/E) 73.479
Price To Earnings QoQ 55.554 %
Price To Earnings YoY 34.891 %
Price To Earnings IPRWA high: 269.298
mean: 120.069
median: 86.718
LIVN: 73.479
low: -315.07
 PE/G Ratio -3.262
 Price To Sales (P/S) 9.568
Price To Sales QoQ 19.557 %
Price To Sales YoY 15.571 %
Price To Sales IPRWA high: 30.65
median: 23.476
mean: 20.18
LIVN: 9.568
low: 0.541
FORWARD MULTIPLES
Forward P/E 51.022
Forward PE/G -2.265
Forward P/S 18.924
EFFICIENCY OPERATIONAL
 Operating Leverage -15.847
ASSET & SALES
 Asset Turnover Ratio 0.14
Asset Turnover Ratio QoQ -1.055 %
Asset Turnover Ratio YoY 9.202 %
Asset Turnover Ratio IPRWA high: 0.371
LIVN: 0.14
median: 0.133
mean: 0.127
low: 0.003
 Receivables Turnover 1.688
Receivables Turnover Ratio QoQ 1.879 %
Receivables Turnover Ratio YoY 10.389 %
Receivables Turnover Ratio IPRWA high: 2.907
mean: 1.882
median: 1.867
LIVN: 1.688
low: 0.47
 Inventory Turnover 0.729
Inventory Turnover Ratio QoQ 7.517 %
Inventory Turnover Ratio YoY 10.246 %
Inventory Turnover Ratio IPRWA high: 1.821
LIVN: 0.729
mean: 0.671
median: 0.548
low: 0.167
 Days Sales Outstanding (DSO) 54.05
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 113.426
Cash Conversion Cycle Days QoQ -4.263 %
Cash Conversion Cycle Days YoY -18.614 %
Cash Conversion Cycle Days IPRWA high: 453.393
mean: 171.849
median: 165.533
LIVN: 113.426
low: -118.454
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 1.23
 CapEx To Revenue -0.089
 CapEx To Depreciation -3.163
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.5 B
 Net Invested Capital 1.6 B
 Invested Capital 1.6 B
 Net Tangible Assets 177.2 M
 Net Working Capital 293.5 M
LIQUIDITY
 Cash Ratio 0.786
 Current Ratio 1.363
Current Ratio QoQ 2.832 %
Current Ratio YoY -52.575 %
Current Ratio IPRWA high: 12.891
mean: 2.707
median: 1.893
LIVN: 1.363
low: 0.168
 Quick Ratio 1.159
Quick Ratio QoQ 3.219 %
Quick Ratio YoY -53.59 %
Quick Ratio IPRWA high: 12.347
mean: 2.057
median: 1.508
LIVN: 1.159
low: 0.437
COVERAGE & LEVERAGE
 Debt To EBITDA 8.154
 Cost Of Debt 1.771 %
 Interest Coverage Ratio 3.545
Interest Coverage Ratio QoQ -13.985 %
Interest Coverage Ratio YoY -22.629 %
Interest Coverage Ratio IPRWA high: 33.446
median: 25.964
mean: 21.048
LIVN: 3.545
low: -66.822
 Operating Cash Flow Ratio 0.066
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 74.89
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 1.895 %
 Revenue Growth 0.886 %
Revenue Growth QoQ -40.256 %
Revenue Growth YoY -719.58 %
Revenue Growth IPRWA high: 20.682 %
median: 12.969 %
mean: 10.186 %
LIVN: 0.886 %
low: -11.548 %
 Earnings Growth -22.523 %
Earnings Growth QoQ -494.172 %
Earnings Growth YoY 125.23 %
Earnings Growth IPRWA high: 216.667 %
mean: 10.501 %
median: 6.383 %
LIVN: -22.523 %
low: -142.105 %
MARGINS
 Gross Margin 66.434 %
Gross Margin QoQ -2.934 %
Gross Margin YoY -2.529 %
Gross Margin IPRWA high: 89.02 %
LIVN: 66.434 %
median: 64.538 %
mean: 62.788 %
low: 1.515 %
 EBIT Margin 10.665 %
EBIT Margin QoQ -14.782 %
EBIT Margin YoY -52.492 %
EBIT Margin IPRWA high: 33.51 %
median: 20.883 %
mean: 20.867 %
LIVN: 10.665 %
low: -143.917 %
 Return On Sales (ROS) 11.797 %
Return On Sales QoQ -21.864 %
Return On Sales YoY -47.45 %
Return On Sales IPRWA high: 35.479 %
mean: 22.18 %
median: 21.965 %
LIVN: 11.797 %
low: -146.78 %
CASH FLOW
 Free Cash Flow (FCF) 50.2 M
 Free Cash Flow Yield 1.453 %
Free Cash Flow Yield QoQ -33.103 %
Free Cash Flow Yield YoY -43.309 %
Free Cash Flow Yield IPRWA high: 4.073 %
LIVN: 1.453 %
median: 0.969 %
mean: 0.909 %
low: -10.193 %
 Free Cash Growth -19.321 %
Free Cash Growth QoQ -164.081 %
Free Cash Growth YoY -117.9 %
Free Cash Growth IPRWA high: 152.763 %
mean: 4.958 %
median: -0.761 %
LIVN: -19.321 %
low: -446.345 %
 Free Cash To Net Income 1.623
 Cash Flow Margin 14.697 %
 Cash Flow To Earnings 1.716
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 1.197 %
Return On Assets QoQ 13.138 %
Return On Assets YoY -46.154 %
Return On Assets IPRWA high: 5.088 %
mean: 2.002 %
median: 1.556 %
LIVN: 1.197 %
low: -17.15 %
 Return On Capital Employed (ROCE) 2.141 %
 Return On Equity (ROE) 0.026
Return On Equity QoQ 11.322 %
Return On Equity YoY -39.145 %
Return On Equity IPRWA high: 0.174
mean: 0.031
median: 0.028
LIVN: 0.026
low: -0.303
 DuPont ROE 2.622 %
 Return On Invested Capital (ROIC) 1.929 %
Return On Invested Capital QoQ -13.225 %
Return On Invested Capital YoY -109.345 %
Return On Invested Capital IPRWA high: 5.899 %
mean: 2.699 %
median: 2.127 %
LIVN: 1.929 %
low: -14.233 %

Six-Week Outlook

Price likely remains range-bound while technical momentum resolves: expect consolidation between $62 and the short-term moving averages near $65–$67 while MRO and negative MACD bias favor occasional downside probes. Liquidity metrics and cash reserves reduce the probability of disorderly moves on company-specific headlines, but leverage (debt/EBITDA ~8.2x) elevates sensitivity to any further margin deterioration. Traders should plan for short-duration setups that respect the present consolidation band and monitor whether DI+/DI- and MACD show a decisive momentum shift before expecting a directional continuation aligned with WMDST’s valuation view.

About LivaNova PLC

LivaNova PLC (NASDAQ:LIVN) designs and manufactures medical devices, offering therapeutic solutions on a global scale. The company operates through three primary segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. In the Cardiopulmonary segment, LivaNova develops and produces products such as oxygenators, heart-lung machines, autotransfusion systems, and perfusion tubing systems, catering to the needs of cardiac surgery. The Neuromodulation segment focuses on the VNS Therapy System, which includes an implantable pulse generator and connective lead designed to stimulate the vagus nerve, providing treatment options for drug-resistant epilepsy and difficult-to-treat depression. The Advanced Circulatory Support segment produces temporary life support products for patients requiring critical care. LivaNova serves a diverse range of healthcare professionals, including perfusionists, neurologists, and neurosurgeons, as well as hospitals and medical institutions. The company distributes its products through a combination of direct sales representatives and independent distributors, ensuring widespread availability of its innovative medical solutions. Headquartered in London, United Kingdom, LivaNova continues to impact the medical device industry with its specialized offerings.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.